REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Citizens JMP Life Sciences Conference being held from May 13-14, 2024 in New York..

加利福尼亚州红木市和波士顿——（商业新闻短讯）——临床阶段生物技术公司Adicet Bio，Inc.（纳斯达克：ACET）今天宣布，总裁兼首席执行官陈绍尔将参加2024年5月13日至14日在纽约举行的2024公民JMP生命科学会议的炉边聊天。该公司发现并开发用于自身免疫性疾病和癌症的同种异体γδT细胞疗法。。

Details of the event are as follows:

活动详情如下：

Date: Tuesday, May 14, 2024

日期：2024年5月14日，星期二

Time: 1:30 p.m. ET

时间：美国东部时间下午1:30

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

演示文稿的现场音频网络广播可以在Adicet Bio网站的投资者部分访问http://www.adicetbio.com.演示后30天内将提供存档的重播。

About Adicet Bio, Inc.

关于Adicet Bio，股份有限公司。

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.

Adicet Bio，Inc.是一家临床阶段生物技术公司，发现并开发用于自身免疫性疾病和癌症的同种异体γδT细胞疗法。Adicet正在推进一条“现成”γδT细胞的管道，该细胞由嵌合抗原受体（CAR）设计，以促进患者的持久活动。

For more information, please visit our website at https://www.adicetbio.com..

欲了解更多信息，请访问我们的网站https://www.adicetbio.com..